The Ministry of Health, India and DCGI have granted market authorization for India's first cell therapy product Chondron ACI by Regenerative Medical Services Regrow. Chondron® ACI is indicated for treatment of cartilage defects of the joints. It uses the body's own autologous cartilage cells which are cultured and multiplied for 3-4 weeks at Regrow's Cell Processing Centre. The cultured cells are then implanted into the patient's damaged joint leading to new cartilage regeneration, avoiding the need of early joint replacement.
Yash Sanghavi, CEO & MD, RMS Regrow said, "We are immensely happy with the FDA approval for Chondron® ACI. We are the first in the country and fourth in the world to achieve this FDA approval. We are creating new age cartilage regeneration procedure which optimizes the chances of healing due to the use of the body's own cells. Patients can now expect a care free future with this treatment and RMS Regrow offers a perfect PEN solution (P -Permanent, E -Easy, N-Natural biological) to the patients."
Echoing similar views on the subject, Satyen Sanghavi, Chief Scientific Officer & Executive Director, RMS Regrow sated, "Today, knee pain is the most common ailment in every household. Osteoarthritis is the most prevalent form of arthritis, affecting over 15 million adults every year, with the number likely to escalate to over 60 million by 2025. Knee implants are expensive and the recovery of the cartilage is not fast. Chondron® ACI has 97% success rate with fast recovery, as observed in over 4-5 lakh cases performed worldwide. RMS Regrow is proud to announce the FDA approval for Chondron® ACI and it is proprietary and patented by RMS Regrow."
Chondron ACI is recommended for patients of 15-65 years age group. It is imperative for a patient to go through rehabilitation process for a minimum of six weeks. The rehabilitation process is performed in the guidance of the doctor and the physiotherapist. There is also medical insurance reimbursement available with Chondron ACI.